Omega-3-Acid Ethyl Esters

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Special Considerations

Brand Names

Europe

Austria: Omacor; Belgium: Omacor; Bulgaria: Omacor; Czech Republic: Omacor; Estonia: Omacor; Finland: Omacor; France: Omacor, Triglistab, Ysomega; Germany: Omacor; Ireland: Omacor; Netherlands: Omacor; Portugal: Omacor, Zodin; Spain: Omacor; UK: Omacor.

North America

USA: Lovaza, Omacor.

Drug combinations

Chemistry

ω-3-Acid Ethyl Esters (2002)

EPA: C~22~H~34~O~2~ Mw: 330.50. (1) 5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (all-Z)-; (2) Ethyl (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoate.

DHA: C~24~H~36~O~2~ Mw: 356.54. (1) 4,7,10,13,16,19-Docosahexaenoic acid, ethyl ester, (all-Z)-; (2) Ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate. CAS-81926-94-5 .

Pharmacologic Category

Antilipemic Agents, Miscellaneous. (ATC-Code: C10AX06).

Mechanism of action

Mechanism not completely defined. Possible mechanisms include inhibition of acyl CoA:1,2 diacylglycerol acyltransferase, increased hepatic β-oxidation, reduction in hepatic synthesis of triglycerides, or increase in plasma lipoprotein lipase activity. May reduce synthesis of triglycerides and VLDL-C in liver. May also inhibit esterification of other fatty acids.

Therapeutic use

Adjunct to diet therapy in the treatment of hypertriglyceridemia (≥500 mg/dL).

Pregnancy and lactiation implications

Embryocidal and maternal effects observed at high doses in animals. There are no adequate studies in pregnant women. Use during pregnancy only if potential benefit outweighs possible risk. Excretion in breast milk unknown (use with caution in nursing women).

Unlabeled use

IgA nephropathy.

Contraindications

Hypersensitivity to ω-3-acid ethyl esters or any component of the formulation.

Warnings and precautions

Use with caution in known allergy or sensitivity to fish. ALT may increase without concurrent AST increase. May increase LDL levels. Prolongation of bleeding time observed (use with caution if coagulopathy or therapeutic anticoagulation). Should be used as adjunct to diet therapy and exercise and only in those with very high triglyceride levels (≥500 mg/dL).

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart